Johnson & Johnson (JNJ) Change in Cash (2009 - 2026)
Johnson & Johnson (JNJ) posted Change in Cash of $2.0 billion for Q1 2026, up 33.9% sequentially from $1.5 billion in Q4 2025, and down 86.23% YoY from $14.4 billion in Q1 2025.
Johnson & Johnson (JNJ) Change in Cash (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Change in Cash data on file, last reported at $2.0 billion in Q1 2026.
- Quarterly Change in Cash fell 86.23% year-over-year to $2.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.8 billion (down 229.11% YoY) and the FY2025 annual result came in at -$4.4 billion, down 295.73% from the prior year.
- Change in Cash rose to $2.0 billion in Q1 2026 per JNJ's latest filing, from $1.5 billion in the prior quarter.
- The five-year high for Change in Cash was $14.4 billion in Q1 2025, with the low at -$19.9 billion in Q2 2025.
- Average Change in Cash over 5 years is -$29.5 million, with a median of -$346.0 million recorded in 2025.
- Year-over-year, Change in Cash soared 416.55% in 2023 and tumbled 3244.03% in 2025.
- Johnson & Johnson's Change in Cash stood at -$4.0 billion in 2022, then jumped by 152.96% to $2.1 billion in 2023, then surged by 93.57% to $4.1 billion in 2024, then tumbled by 64.17% to $1.5 billion in 2025, then surged by 33.9% to $2.0 billion in 2026.
- Business Quant data shows JNJ's Change in Cash at $2.0 billion in Q1 2026, $1.5 billion in Q4 2025, and -$346.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -1.99 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 1.98 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 4.16 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 5.70 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -9.29 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 65.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 563.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 392.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 1.98 Bn |
| Dec 28, 2025 | 1.48 Bn |
| Sep 28, 2025 | -346.00 Mn |
| Jun 29, 2025 | -19.90 Bn |
| Mar 30, 2025 | 14.37 Bn |
| Dec 29, 2024 | 4.13 Bn |
| Sep 29, 2024 | -4.90 Bn |
| Jun 30, 2024 | -595.00 Mn |
| Mar 31, 2024 | 3.61 Bn |
| Dec 31, 2023 | 2.13 Bn |
| Oct 1, 2023 | -1.46 Bn |
| Jul 2, 2023 | -5.68 Bn |
| Apr 2, 2023 | 12.74 Bn |
| Jan 1, 2023 | -3.98 Bn |
| Apr 3, 2022 | -4.02 Bn |
| Oct 3, 2021 | 3.27 Bn |
| Jul 4, 2021 | 1.66 Bn |
| Apr 4, 2021 | -1.31 Bn |
| Jan 3, 2021 | -4.98 Bn |
| Sep 27, 2020 | 7.79 Bn |